Client News
OKYO Pharma Limited: Director Acquires SharesLondon and New York, NY, 30 March, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company’s ADSs on NASDAQ at a price of US$1.41 per ADS (which would be equivalent to the purchase of 715,000 ordinary shares of no par value (“Ordinary Shares”) at a price of £0.0176 each).
|
1. |
Details of PDMR / person closely associated |
|
|
a) |
Name |
Gabriele Cerrone |
|
2. |
Reason for the notification |
|
|
a) |
Position / status |
Chairman |
|
b) |
Initial notification /amendment |
Initial notification |
|
3. |
Details of the issuer |
|
|
a) |
Name |
OKYO Pharma Limited |
|
b) |
LEI |
213800VVN5CB56Y15A05 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument |
ADSs representing 65 Ordinary Shares of no par value |
|
b) |
Identification code of the Financial Instrument |
ISIN for OKYO Pharma Limited GG00BD3FV870 |
|
c) |
Nature of the transaction |
Market Purchase |
|
d) |
Price(s) and volume(s) |
$1.41 – 11,000
|
|
f) |
Date of the transaction |
28 March 2023 |
|
g) |
Place of the transaction |
NASDAQ |
Director Acquires Shares – 07:00:08 30 Mar 2023 – OKYO News article | London Stock Exchange
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.